Roundtable Discussion: Participants Discuss Treatment in Transplant-Ineligible DLBCL
August 20th 2021Grzegorz S. Nowakowski, MD and Stephen D. Smith lead other participants of a Case Based Roundtable event in a discussion around treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.
Roundtable Discussion: Lee and Participants Debate Frontline Therapy in Intermediate-Risk RCC
August 17th 2021A 59-year-old Black woman received a diagnosis of clear cell renal cell carcinoma. Chung-Han Lee, Md, PhD and a group of other physicians discussed the patient's case during a Case-Based Roundtable event.
Vesole Discusses the Benefits and Challenges of Daratumumab in Patients With NDMM
August 15th 2021At a live virtual event, David H. Vesole, MD, PhD, explained to other clinicians the use of daratumumab in the treatment of patients with newly diagnosed multiple myeloma who are either eligible or ineligible for autologous stem cell transplant.
Roundtable Discussion: Perez Explores Therapeutic Options in RET-Mutated NSCLC
August 8th 2021Molecular testing practices and treatment decisions can vary for patients with non–small cell lung cancer. Cesar A. Perez, MD, and a group of other physicians discussed next steps in care for a patient with non–small cell lung cancer whose molecular test results revealed a RET mutation.
Combination of Tafasitamab/Lenalidomide Demonstrates Positive Efficacy in DLBCL
August 6th 2021The laboratory results, lymph node biopsy, imaging studies and other information of a 75-year-old patient with diffuse large B-cell lymphoma were brought into consideration during a Targeted Oncology Case-Based Roundtable discussion around treatment with tafasitamab and lenalidomide (Revlimid).
PARP Inhibitors an Option for Metastatic Castration-Resistant Prostate Cancer
August 5th 2021During a Targeted Oncology Case-Based Roundtable event, Tian Zhang, MD, MHS, an assistant professor of Medicine at Duke Cancer Institute, discusses the case of a 60-year-old patients with metastatic castration-resistant prostate cancer.